Vaccines tested against L. donovani | |||||
Antigen | Source of antigen | Vaccine delivery | Animal model | Outcome | Reference |
| |||||
p36 LACK | Multiple species | DNA vaccine | Mouse | No protection | Melby et al., 2001 [58] |
dp72 | L. donovani | Native protein antigen | Mouse | Partial protection | Jaffe et al., 1990 [59] |
A2 | L. donovani | Recombinant protein | Mouse | Protection | Ghosh et al., 2001 [60] |
A2 | L. donovani | DNA vaccine | Mouse | Protection | Ghosh et al., 2001 [61] |
HASPB1 | L. donovani | Recombinant protein | Mouse | Protection | Stager et al., 2000 [8] |
ORFF | L. donovani | Recombinant protein | Mouse | Partial protection | Tewary et al., 2004 [62] |
ORFF | L. donovani | DNA vaccine + recombinant protein | Mouse | Partial protection | Tewary et al., 2005 [63] |
ORFF | L. donovani | DNA vaccine | Mouse | Partial protection | Sukumaran et al., 2003 [64] |
KMP-11 | L. donovani | DNA vaccine | Hamster | Protection | Basu et al., 2005 [65] |
KMP-11 | L. donovani | DNA vaccine | Mouse | Partial protection | Bhaumik et al., 2009 [66] |
gp36 | L. major | Recombinant protein expressed in bacilli | Mouse | Partial protection | McSorely et al., 1997 [67] |
gp36 | L. donovani | Native protein in cationic liposomes | Mouse | Partial protection | Bhowmick et al., 2008 [68] |
SLA | L. donovani | Native proteins in cationic liposomes | Mouse | Protection | Bhowmick et al., 2007 [69] |
SLA | L. donovani | Native proteins | Mouse | Protection | Tewary et al., 2004 [70] |
LD9, LD72, LD51, LD31 | L. donovani | Native proteins in cationic liposomes | Mouse | Protection | Bhowmick and Ali, 2009 [71] |
Leishmanial antigens | L. donovani | Native proteins in liposomes | Mouse | Protection | Mazumdar et al., 2004 [72] |
F14 | L. donovani | Recombinant protein | Hamster | Partial protection | Bhardwaj et al., 2009 [73] |
γ-GCS | L. donovani | DNA vaccine | Mouse | Partial protection | Carter et al., 2007 [74] |
FML | L. donovani | Native protein | Mouse | Partial protection | Palanik-de-Sousa et al., 1994 [75] |
FML | L. donovani | Native protein | Mouse | Partial protection | Santos et al., 1999 [76] |
FML | L. donovani | Formulation with QuilA saponin | Dog | Protection | Borja-Cabrera et al., 2002 [77] |
Leishmune (FML) | L. donovani | Recombinant protein | Dog | Partial protection | Saraiva et al., 2006 [78] |
Leishmune (FML) | L. donovani | Recombinant protein | Dog | Protection | Nogueira et al., 2005 [79] |
H2A, H2B, H3, H4 and LACK | L. donovani | Multiunit DNA vaccine | Dog | Partial protection | Saldarriaga et al., 2006 [80] |
LPG | L. donovani | Purified glycolipid + BCG | Hamster and mouse | No protection | Tonui et al., 2003 [81] |
CP: cysteine proteinase; CTE: C-terminal extension; BCG: Mycobacterium bovis bacillus Calmette-Guerin; SLA: soluble leishmanial antigens; FML: fucose-mannose ligand; LiESAp: Leishmania infantum excreted-secreted antigen purified; LPG: lipophosphoglycan.